Evidence map›Paper›PMID 39442039›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2025

"Lupus Myelitis" Revisited: A Retrospective Single-Center Study of Myelitis Associated With Rheumatologic Disease.

Jonathan D Krett, Angeliki G Filippatou, Paula Barreras, Carlos A Pardo, Allan C Gelber, Elias S Sotirchos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jonathan D KrettFrom the Division of Neuroimmunology and Neurological Infections (J.D.K., A.G.F., P.B., C.A.P., E.S.S.), Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD; Multiple Sclerosis and Neuroimmunology Center (P.B.), Department of Neurology and Neurosurgery, Cedars-Sinai Medical Center, University of California, Los Angeles; and Division of Rheumatology (A.C.G.), Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0003-4964-3341
Angeliki G FilippatouFrom the Division of Neuroimmunology and Neurological Infections (J.D.K., A.G.F., P.B., C.A.P., E.S.S.), Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD; Multiple Sclerosis and Neuroimmunology Center (P.B.), Department of Neurology and Neurosurgery, Cedars-Sinai Medical Center, University of California, Los Angeles; and Division of Rheumatology (A.C.G.), Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0003-0419-233X
Paula BarrerasFrom the Division of Neuroimmunology and Neurological Infections (J.D.K., A.G.F., P.B., C.A.P., E.S.S.), Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD; Multiple Sclerosis and Neuroimmunology Center (P.B.), Department of Neurology and Neurosurgery, Cedars-Sinai Medical Center, University of California, Los Angeles; and Division of Rheumatology (A.C.G.), Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0002-3837-7183
Carlos A PardoFrom the Division of Neuroimmunology and Neurological Infections (J.D.K., A.G.F., P.B., C.A.P., E.S.S.), Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD; Multiple Sclerosis and Neuroimmunology Center (P.B.), Department of Neurology and Neurosurgery, Cedars-Sinai Medical Center, University of California, Los Angeles; and Division of Rheumatology (A.C.G.), Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0002-4128-5335
Allan C GelberFrom the Division of Neuroimmunology and Neurological Infections (J.D.K., A.G.F., P.B., C.A.P., E.S.S.), Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD; Multiple Sclerosis and Neuroimmunology Center (P.B.), Department of Neurology and Neurosurgery, Cedars-Sinai Medical Center, University of California, Los Angeles; and Division of Rheumatology (A.C.G.), Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Elias S SotirchosFrom the Division of Neuroimmunology and Neurological Infections (J.D.K., A.G.F., P.B., C.A.P., E.S.S.), Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD; Multiple Sclerosis and Neuroimmunology Center (P.B.), Department of Neurology and Neurosurgery, Cedars-Sinai Medical Center, University of California, Los Angeles; and Division of Rheumatology (A.C.G.), Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0002-8812-1637

Funding

Prediction of risk of disability worsening and inflammatory disease activity in MS utilizing multimodal prediction algorithmsK23NS117883 · NINDS · JOHNS HOPKINS UNIVERSITY · PI SOTIRCHOS, ELIAS S · 2020 to 2024
$918k
NINDS NIH HHS K23 NS117883
6 · The paper itself

Abstract

BACKGROUND AND

objectivesPrevious reports of patients with myelitis associated with rheumatologic disease may have had unrecognized aquaporin-4 (AQP4)-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) or myelin oligodendrocyte glycoprotein (MOG)-IgG-associated disease (MOGAD). We clinicoradiologically and serologically characterized patients with myelitis associated with rheumatologic disease evaluated in the era of availability of MOG-IgG and more sensitive AQP4-IgG cell-based assays.

methodsA retrospective cohort (2018-2023) at Johns Hopkins Medicine with diagnoses of myelopathy and rheumatologic comorbidity was identified by electronic medical record (EMR) query. All patients with myelitis unrelated to typical multiple sclerosis (MS) were included and analyzed by chart review.

resultsOf 238 patients identified by EMR query, 197 were excluded (148 not meeting prespecified inclusion criteria, 49 had typical MS), resulting in 41 patients for review. The mean age at myelitis onset was 44 ± 15 years; 39 (95%) were female. Rheumatologic diagnoses included 17 (41.5%) with systemic lupus erythematosus (SLE), 10 (24.3%) Sjögren syndrome (SS), 6 (15%) undifferentiated connective tissue disease (UCTD), 5 (12%) combinations of SLE/SS/UCTD with antiphospholipid antibody syndrome, 1 (2.4%) rheumatoid arthritis, 1 (2.4%) psoriatic arthritis, and 1 (2.4%) Behçet disease. 20 patients (49%) were diagnosed with AQP4-IgG seropositive NMOSD, 3 (7%) with MOGAD, and 18 (44%) had "double-seronegative" myelitis. Of these 18, 3 were diagnosed with AQP4-IgG seronegative NMOSD, 1 neuro-Behçet disease, and 14 other (unclassifiable) myelitis. Excluding 1 patient with neuro-Behçet disease, 18 (90%) of 20 AQP4-IgG seropositive patients had longitudinally extensive cord lesions compared with 5 (29%; DISCUSSION: Approximately half of our rheumatologic disease cohort with myelitis unrelated to MS had AQP4-IgG seropositive NMOSD while MOGAD accounted for a small but clinically relevant proportion of patients. Further research is needed to characterize myelitis etiology in patients who are seronegative for both AQP4-IgG and MOG-IgG.

Indexed as

MyelitisAdultAquaporin 4FemaleHumansLupus Erythematosus, SystemicMaleMiddle AgedMyelin-Oligodendrocyte GlycoproteinRetrospective StudiesRheumatic DiseasesAquaporin 4Myelin-Oligodendrocyte Glycoprotein

Identifiers

PMID39442039
PMCPMC11727606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.